Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 2/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.48 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.40 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21889851 | 0.79 | AOC3 (0.61) | AOC3SIGMAR1TMEM97NPC1RAB9A | |
| SCHEMBL21889053 | 0.78 | SIGMAR1 (0.43) | SIGMAR1HSD17B2TMEM97NPC1RAB9A | |
| SCHEMBL21889170 | 0.74 | AOC3 (1.00) | AOC3 | |
| SCHEMBL21889307 | 0.74 | AOC3 (0.39) | AOC3SIGMAR1TMEM97 | |
| SCHEMBL12776151 | 0.74 | SIGMAR1 (0.47) | AOC3SIGMAR1TMEM97NPC1RAB9A | |
| SCHEMBL2645379 | 0.73 | HSD17B2 (0.49) | HSD17B2NPC1RAB9ANR1H2NR1H3 | |
| SCHEMBL21914567 | 0.72 | AOC3 (0.50) | AOC3SIGMAR1HSD17B2NPC1RAB9A | |
| SCHEMBL21889148 | 0.71 | AOC3 (0.40) | AOC3SIGMAR1 | |
| SCHEMBL19231182 | 0.69 | SIGMAR1 (0.64) | AOC3SIGMAR1TMEM97NPC1RAB9A | |
| SCHEMBL17803244 | 0.68 | SIGMAR1 (0.55) | AOC3SIGMAR1TMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3626699-B1 | SSAO INHIBITOR | SHANDONG DANHONG PHARMACEUTICAL CO LTD (CN) | 2023-07-12 | — | — | EP | disclosed |
| US-20210198220-A1 | SSAO INHIBITOR | SHANDONG DANHONG PHARMACEUTICAL CO LTD (CN) | 2021-07-01 | — | — | US | disclosed |
| EP-3626699-A1 | SSAO INHIBITOR | Shandong Danhong Pharmaceutical Co., Ltd. (CN) | 2020-03-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198220-A1 | SSAO INHIBITOR | SSB, ASAH2, AOX1 | AOC3 53/4885SIGMAR1 1637/4885HSD17B2 544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.